Semavic® ning uch
ta’sirini o’zingiz
uchun kashf eting

Ta’sir etuvchi modda semaglutid

• Semavic® jiddiy yurak-qon tomir kasalliklari xavfini kamaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

• Semavic® triglitserid va xolesterin darajasini pasaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

• Semavic® sistolik qon bosimini pasaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

• Semavic® 2-toifa qandli diabet (qon plazma glyukozasi va glyukozalangan gemoglobin (HbA1c)) bo’lgan kattalarda qondagi glyukoza darajasini pasaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

• Semavic® ishtahani bostiradi va kun davomida kaloriya iste’molini 18–35 % ga kamaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

• Semavic® asosan yog’ massasini kamaytirish orqali tana vaznini kamaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

Semavic® bemorlarning yurak-qon tomir salomatligini himoya qilishga yordam berishi ko’rsatilgan ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar (2) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes}

Semavic® ko’pchilik bemorlarda HbA1c* darajasini 7 % dan past darajada kamaytirishi va ushlab turishi ko’rsatilgan ^{(3) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol (4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol (5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol}

**HbA1c biokimyoviy ko’rsatkich bo’lib, oxirgi 3 oy davomida qondagi o’rtacha glyukoza miqdorini aks ettiradi. Qandli diabetda (glyukoza so’rilishining buzilishi bilan bog’liq kasallik, natijada giperglikemiya – qondagi glyukoza darajasining doimiy o’sishi) glyukoza gemoglobinga qo’shilib, glyukozalangan gemoglobin (belgilangan HbA1c) hosil bo’ladi. Qonda glyukoza darajasi qanchalik yuqori bo’lsa, gemoglobin shunchalik ko’p glyukozalangan gemoglobinga aylanadi.

SUSTAIN 4
tadqiqoti ^{(3) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol} :

SUSTAIN 7
tadqiqoti ^{(4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol} :

SUSTAIN FORTE
tadqiqoti ^{(5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol} :

HbA1c
boshlang’ich darajasi

Начальный уровень
HbA1c

SUSTAIN 4
tadqiqoti ^{(3) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol} :

8,1%

Haftasiga 0,5 mg
semaglutid

-1,2%

8,2%

Haftasiga 1 mg
semaglutid

-1,5%

 

SUSTAIN 7
tadqiqoti ^{(4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol} :

8,3%

Haftasiga 0,5 mg
semaglutid

-1,4%

8,2%

Haftasiga 1 mg
semaglutid

-1,6%

 

SUSTAIN FORTE
tadqiqoti ^{(5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol} :

8,8%

Haftasiga 1 mg
semaglutid

-1,9%

HbA1cning kuzativ
oxiridagi darajasi

7% dan
PASTROQ

Qandli diabet bilan og rigan kattalar uchun HbA1c ning 7,0 % dan kam bo lishi yetarli ^{(6) Qandli diabet bilan og’rigan bemorlarga ixtisoslashtirilgan tibbiy yordam ko’rsatish algoritmlari}

HbA1c бойынша терапия мақсаттарын жеке таңдау алгоритмі

Klinik xususiyatlar/xavflar	Bemor toifalari
	Yosh	O’rta yosh/qarilik	Qarilik/keksalik
			Funktsional jihatdan mustaqil	Funktsional jihatdan qaram
				Keksalik asteniyasi va/yoki dementsiyasiz	Keksa asteniyali va/yoki demantsiyali	Hayotning yakuniy bosqichi
Aterosklerotik yurak-qon tomir kasalliklari (3) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol va/yoki og’ir gipoglikemiya xavfi (4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol yo’q	<6,5%	<7,0%	<7,5%	<8,0%	<8,5%	Gipoglikemiya va gipoglikemiya belgilaridan saqlaning
Aterosklerotik yurak-qon tomir kasalliklari va/yoki og’ir gipoglikemiya xavfi mavjud	<7,0%	<7,5%	<8,0%

Semavic® bemorga vazn yo’qotishga ishonchli yordam beradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar (4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol (5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol}

Semavic (faol tarkibiy qism semaglutid) faqat vazn yo’qotish uchun ko’rsatilmaydi. Klinik tadqiqotlarda vazn o’zgarishi ikkinchi darajali yakuniy nuqta edi.

SUSTAIN 7
tadqiqoti ^{(4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol} :

SUSTAIN FORTE
tadqiqoti ^{(5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol} :

Boshlang’ich vazn

Boshlang’ich vazn

SUSTAIN 7
tadqiqoti ^{(4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol} :

94,8 kg

Haftasiga 0,5 mg
semaglutid

-4,2 kg

94,8 kg

Haftasiga 1 mg
semaglutid

-5,8 kg

 

SUSTAIN FORTE
tadqiqoti ^{(5) Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol} :

99,4 kg

Haftasiga 1 mg
semaglutid

-5,67 kg

Qandli diabet bilan og’rigan ko’pchilik kattalar uchun HbA1c 7,0 % dan kam bo’lgan maqsad ko’rsatkichi yetarli ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Semanavik® bilan vazn yo’qotish, birinchi navbatda, yog ’to’qimalarining yo’qolishi bilan bog’liq bo’lib, bu mushak massasini yo’qotishdan 3 baravar ko’p ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Semavic® ishtahani bostiradi va kun davomida kaloriya iste’molini 18–35 % ga kamaytiradi ^{(1) Semavic® dori vositasidan tibbiy foydalanish bo’yicha ko’rsatmalar}

Semavic® ovqatga, ayniqsa yog’li ovqatlarga bo’lgan istakni bostiradi